Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$1.35 +9.8%	$1.44	$0.65 ▼ $17.00	$22.97M	1.19	268,600 shs	2.12 million shs
NBY NovaBay Pharmaceuticals	$0.91 -14.9%	$0.64	$0.44 ▼ $1.25	$5.30M	0.4	1.31 million shs	1.67 million shs
PRPH ProPhase Labs	$0.33 -1.9%	$0.37	$0.22 ▼ $3.00	$13.66M	-0.48	15.45 million shs	686,071 shs
TXMD TherapeuticsMD	$1.10 +1.8%	$1.14	$0.70 ▼ $2.44	$12.73M	0.42	21,600 shs	21,585 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	0.00%	+1.50%	-20.12%	+92.03%	-90.96%
NBY NovaBay Pharmaceuticals	0.00%	+47.38%	+39.74%	+59.75%	+68.23%
PRPH ProPhase Labs	0.00%	-5.87%	-21.99%	+2.62%	-88.38%
TXMD TherapeuticsMD	0.00%	-5.98%	-3.52%	-24.14%	-34.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTXR Citius Pharmaceuticals	2.5852 of 5 stars	3.3	4.0	1.1	0.8	1.3
NBY NovaBay Pharmaceuticals	0.3624 of 5 stars	1.5	0.0	0.6	0.0	1.3
PRPH ProPhase Labs	1.2496 of 5 stars	0.0	5.0	3.1	0.0	0.6
TXMD TherapeuticsMD	0.1451 of 5 stars	0.0	3.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTXR Citius Pharmaceuticals	2.50	Moderate Buy	$53.00	3,825.93% Upside
NBY NovaBay Pharmaceuticals	3.00	Buy	$0.85	-6.60% Downside
PRPH ProPhase Labs	0.00	N/A	N/A	N/A
TXMD TherapeuticsMD	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NBY, CTXR, PRPH, and TXMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/30/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/9/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$3.97 per share	N/A
NBY NovaBay Pharmaceuticals	$9.78M	0.54	N/A	N/A	$4.25 per share	0.21
PRPH ProPhase Labs	$6.77M	2.02	N/A	N/A	$0.28 per share	1.17
TXMD TherapeuticsMD	$1.76M	7.23	N/A	N/A	$2.36 per share	0.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	1.08	N/A	N/A	-60.03%	-33.83%	N/A
NBY NovaBay Pharmaceuticals	-$9.64M	-$53.72	N/A	N/A	N/A	-102.72%	-7,293.78%	-158.41%	N/A
PRPH ProPhase Labs	-$53.36M	-$1.26	N/A	N/A	N/A	N/A	-262.42%	-76.48%	11/12/2025 (Estimated)
TXMD TherapeuticsMD	-$2.18M	N/A	0.00	∞	N/A	-17.94%	-2.01%	-1.40%	11/10/2025 (Estimated)

Latest NBY, CTXR, PRPH, and TXMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	PRPH ProPhase Labs	-$0.15	-$0.11	+$0.04	-$0.11	$3.55 million	$1.25 million
8/12/2025	Q3 2025	CTXR Citius Pharmaceuticals	-$0.76	-$0.80	-$0.04	-$0.80	$1.92 million	$1.92 million
8/12/2025	Q2 2025	TXMD TherapeuticsMD	N/A	$0.05	N/A	$0.05	N/A	$0.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRPH ProPhase Labs	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTXR Citius Pharmaceuticals	N/A	0.47	0.14
NBY NovaBay Pharmaceuticals	N/A	1.15	0.91
PRPH ProPhase Labs	0.20	0.96	0.93
TXMD TherapeuticsMD	N/A	2.89	2.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTXR Citius Pharmaceuticals	16.88%
NBY NovaBay Pharmaceuticals	23.25%
PRPH ProPhase Labs	9.45%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
CTXR Citius Pharmaceuticals	10.70%
NBY NovaBay Pharmaceuticals	0.10%
PRPH ProPhase Labs	9.60%
TXMD TherapeuticsMD	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTXR Citius Pharmaceuticals	20	17.01 million	15.19 million	Optionable
NBY NovaBay Pharmaceuticals	30	5.82 million	4.88 million	Not Optionable
PRPH ProPhase Labs	130	41.54 million	37.55 million	Optionable
TXMD TherapeuticsMD	420	11.57 million	11.31 million	Optionable

NBY, CTXR, PRPH, and TXMD Headlines

Recent News About These Companies

TherapeuticsMD Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

TherapeuticsMD: Q2 Earnings Snapshot

August 12, 2025 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2025 Financial Results

August 12, 2025 | businesswire.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 16, 2025 | marketwatch.com

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

TherapeuticsMD Inc. stock rises Monday, still underperforms market

May 12, 2025 | marketwatch.com

TherapeuticsMD Inc. stock outperforms competitors despite losses on the day

April 8, 2025 | marketwatch.com

TherapeuticsMD Announces Full Year 2024 Financial Results

March 27, 2025 | businesswire.com

TherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo Finance

March 26, 2025 | finance.yahoo.com

TherapeuticsMD Inc’s Stock Drama: Could This Be a Game-Changer for TXMD Investors?

January 7, 2025 | bovnews.comB

TherapeuticsMD Inc (TXMD) Stock: A Deeper Look at Its True Potential

January 3, 2025 | bovnews.comB

TherapeuticsMD Inc. stock remains steady Friday, still outperforms market

December 27, 2024 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains

November 23, 2024 | marketwatch.com

TherapeuticsMD Shifts Focus with Lower Q3 Losses

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Reports Reduced Losses Amid Strategic Shift

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Announces Third Quarter 2024 Financial Results

November 13, 2024 | finance.yahoo.com

TherapeuticsMD Inc. stock remains steady Monday, underperforms market

November 12, 2024 | marketwatch.com

TherapeuticsMD (NASDAQ:TXMD) Stock, Option Chain

November 6, 2024 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBY, CTXR, PRPH, and TXMD Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

$1.35 +0.12 (+9.76%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.35 0.00 (0.00%)

As of 08/22/2025 07:52 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

NovaBay Pharmaceuticals NYSE:NBY

$0.91 -0.16 (-14.94%)

As of 08/22/2025 04:00 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

ProPhase Labs NASDAQ:PRPH

$0.33 -0.01 (-1.88%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.33 +0.00 (+1.28%)

As of 08/22/2025 07:42 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

TherapeuticsMD NASDAQ:TXMD

$1.10 +0.02 (+1.84%)

Closing price 08/22/2025 03:55 PM Eastern

Extended Trading

$1.08 -0.02 (-1.81%)

As of 08/22/2025 07:40 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time